Skip to main content

MW 384.2 Da, Purity >98%. Potent, selective, reversible proteasome inhibitor (Ki = 0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50 = 7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis.

Be the first to review this product! Submit a review

Publications

Key facts

CAS number
179324-69-7
Purity
> 98%
Form
Solid
Molecular weight
384.2 Da
Molecular formula
C19H25BN4O4
PubChem identifier
387447
Nature
Synthetic

Alternative names

Recommended products

MW 384.2 Da, Purity >98%. Potent, selective, reversible proteasome inhibitor (Ki = 0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50 = 7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis.

Key facts

Purity
> 98%
PubChem identifier
387447
Solubility

The solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.

Soluble in DMSO to 100 mM.

Soluble in ethanol to 90 mM.

Biochemical name
Bortezomib
Biological description

Potent, selective, reversible proteasome inhibitor (Ki = 0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50 = 7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis.

Canonical SMILES
B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Isomeric SMILES
B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChIKey
GXJABQQUPOEUTA-RDJZCZTQSA-N
IUPAC name
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The proteasome is a large complex responsible for degrading ubiquitinated proteins which is essential for maintaining cellular protein homeostasis. PSMD8 also known as Proteasome 19S S5A/ASF along with other components like Neutrophil Elastase and various proteasome subunits (e.g. PSMB1 PSMA3 PSMD12) play critical roles within the 26S proteasome system. The 26S proteasome is known for its multi-subunit structure which includes a 20S core particle and 19S regulatory particles. Each subunit has a distinct mass and function contributing to the regulatory mechanisms. PSMD8 is expressed in many tissues facilitating its role in proteolytic processes.

Biological function summary

These proteasome components have key functions in the ubiquitin-proteasome pathway which is integral for degrading misfolded or damaged proteins. PSMD8 and its associated subunits are part of the 26S proteasome complex. This large complex helps regulate various cellular processes including DNA repair cell cycle progression and signal transduction. The activity of different subunits like PSMD2 and PSMB4 participates in recognizing unfolding and translocating targeted proteins into the proteolytic chamber for controlled degradation.

Pathways

The proteasome system including PSMD8 and other subunits plays a significant role in the ubiquitin-proteasome pathway and the cell cycle progression pathway. This system impacts cellular processes such as antigen processing and presentation which are important for immune responses. Moreover the 26S proteasome interacts with proteins like p53 and cyclins highlighting its involvement in regulating cell cycle checkpoints and apoptosis. These interactions demonstrate the proteasome’s central role in maintaining cellular integrity and function.

Associated diseases and disorders

Dysregulation of proteasome activity which involves components like PSMD8 has been implicated in certain cancers and neurodegenerative diseases. For example the proteasome inhibitor bortezomib has been used successfully in treating multiple myeloma targeting proteasome activity to induce apoptosis in cancer cells. Abnormal proteasome function is also linked to Parkinson’s disease as it affects protein degradation in neurons. The relationship between proteasome dysfunction and these conditions underlines the importance of targeting subunits such as PSMB5/MB1 and PSMD14 in therapeutic strategies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

0 product images

    Downloads

    Product protocols

    For this product, it's our understanding that no specific protocols are required. You can:

    Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

    For licensing inquiries, please contact partnerships@abcam.com